BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanbayashi T, Inoue Y, Kawanishi K, Takasaki H, Aizawa R, Takahashi K, Ogawa Y, Abe M, Hishikawa Y, Shimizu T. CSF hypocretin measures in patients with obstructive sleep apnea: CSF hypocretin measures in patients with obstructive sleep apnea. Journal of Sleep Research 2003;12:339-41. [DOI: 10.1046/j.0962-1105.2003.00373.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Lal C, Weaver TE, Bae CJ, Strohl KP. Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management. Ann Am Thorac Soc 2021;18:757-68. [PMID: 33621163 DOI: 10.1513/AnnalsATS.202006-696FR] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Terada J, Nakamura A, Zhang W, Yanagisawa M, Kuriyama T, Fukuda Y, Kuwaki T. Ventilatory long-term facilitation in mice can be observed during both sleep and wake periods and depends on orexin. J Appl Physiol (1985) 2008;104:499-507. [PMID: 18032578 DOI: 10.1152/japplphysiol.00919.2007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 4.2] [Reference Citation Analysis]
3 Knudsen S, Jennum PJ, Alving J, Sheikh SP, Gammeltoft S. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Sleep 2010;33:169-76. [PMID: 20175400 DOI: 10.1093/sleep/33.2.169] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
4 Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T. Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. J Appl Physiol (1985) 2007;102:241-8. [PMID: 16959906 DOI: 10.1152/japplphysiol.00679.2006] [Cited by in Crossref: 107] [Cited by in F6Publishing: 98] [Article Influence: 6.7] [Reference Citation Analysis]
5 Deguchi K, Kono S, Deguchi S, Morimoto N, Ikeda M, Kurata T, Ikeda Y, Matsuura T, Kanbayashi T, Takahashi T, Abe K. A patient with anti-aquaporin 4 antibody presenting hypersomnolence as the initial symptom and symmetrical hypothalamic lesions. J Neurol Sci 2012;312:18-20. [PMID: 21917270 DOI: 10.1016/j.jns.2011.08.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
6 Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Medicine Reviews 2005;9:269-310. [DOI: 10.1016/j.smrv.2005.03.004] [Cited by in Crossref: 234] [Cited by in F6Publishing: 147] [Article Influence: 13.8] [Reference Citation Analysis]
7 Kuwaki T. Orexinergic modulation of breathing across vigilance states. Respir Physiol Neurobiol 2008;164:204-12. [PMID: 18455970 DOI: 10.1016/j.resp.2008.03.011] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
8 Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. The Lancet Neurology 2008;7:649-62. [DOI: 10.1016/s1474-4422(08)70140-6] [Cited by in Crossref: 93] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
9 Asai H, Hirano M, Furiya Y, Udaka F, Morikawa M, Kanbayashi T, Shimizu T, Ueno S. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. Clinical Neurology and Neurosurgery 2009;111:341-4. [DOI: 10.1016/j.clineuro.2008.11.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
10 Nozaki H, Shimohata T, Kanbayashi T, Sagawa Y, Katada S, Satoh M, Onodera O, Tanaka K, Nishizawa M. A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. Sleep Med 2009;10:253-5. [PMID: 18226957 DOI: 10.1016/j.sleep.2007.11.022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
11 Kuwaki T, Zhang W. Orexin neurons as arousal-associated modulators of central cardiorespiratory regulation. Respiratory Physiology & Neurobiology 2010;174:43-54. [DOI: 10.1016/j.resp.2010.04.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
12 Liguori C, Mercuri NB, Nuccetelli M, Izzi F, Cordella A, Bernardini S, Placidi F. Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk? Sleep Medicine 2019;56:171-6. [DOI: 10.1016/j.sleep.2019.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
13 Mullins AE, Kam K, Parekh A, Bubu OM, Osorio RS, Varga AW. Obstructive Sleep Apnea and Its Treatment in Aging: Effects on Alzheimer's disease Biomarkers, Cognition, Brain Structure and Neurophysiology. Neurobiol Dis 2020;145:105054. [PMID: 32860945 DOI: 10.1016/j.nbd.2020.105054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
14 Baumann CR, Bassetti CL. Hypocretins (orexins) and sleep–wake disorders. The Lancet Neurology 2005;4:673-82. [DOI: 10.1016/s1474-4422(05)70196-4] [Cited by in Crossref: 102] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
15 Kanbayashi T, Kodama T, Kondo H, Satoh S, Inoue Y, Chiba S, Shimizu T, Nishino S. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 2009;32:181-7. [PMID: 19238805 DOI: 10.1093/sleep/32.2.181] [Cited by in Crossref: 118] [Cited by in F6Publishing: 85] [Article Influence: 9.1] [Reference Citation Analysis]
16 Carrive P, Kuwaki T. Orexin and Central Modulation of Cardiovascular and Respiratory Function. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 157-96. [DOI: 10.1007/7854_2016_46] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
17 Liguori C, Maestri M, Spanetta M, Placidi F, Bonanni E, Mercuri NB, Guarnieri B. Sleep-disordered breathing and the risk of Alzheimer's disease. Sleep Med Rev 2021;55:101375. [PMID: 33022476 DOI: 10.1016/j.smrv.2020.101375] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
18 Plazzi G, Serra L, Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008;12:109-28. [PMID: 18282773 DOI: 10.1016/j.smrv.2007.08.010] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
19 Baumann CR, Bassetti CL. Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. Sleep Medicine Reviews 2005;9:253-68. [DOI: 10.1016/j.smrv.2005.01.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
20 Williams RH, Burdakov D. Hypothalamic orexins/hypocretins as regulators of breathing. Expert Rev Mol Med 2008;10:e28. [PMID: 18828950 DOI: 10.1017/S1462399408000823] [Cited by in Crossref: 59] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]